Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

@article{Roybal2016EngineeringTC,
  title={Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors},
  author={Kole T. Roybal and Jasper Z. Williams and Leonardo Morsut and Levi J. Rupp and Isabel Kolinko and Joseph H. Choe and Whitney J. Walker and Krista A. McNally and Wendell A Lim},
  journal={Cell},
  year={2016},
  volume={167},
  pages={419-432.e16}
}
Redirecting T cells to attack cancer using engineered chimeric receptors provides powerful new therapeutic capabilities. However, the effectiveness of therapeutic T cells is constrained by the endogenous T cell response: certain facets of natural response programs can be toxic, whereas other responses, such as the ability to overcome tumor immunosuppression, are absent. Thus, the efficacy and safety of therapeutic cells could be improved if we could custom sculpt immune cell responses… CONTINUE READING

Figures and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 98 CITATIONS, ESTIMATED 38% COVERAGE

Redirecting T cells to treat solid pediatric cancers

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer.

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Are the biomedical sciences ready for synthetic biology?

VIEW 1 EXCERPT
CITES BACKGROUND

A standard for near-scarless plasmid construction using reusable DNA parts

VIEW 1 EXCERPT
CITES BACKGROUND

Advances in Engineering Cells for Cancer Immunotherapy

VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2016
2020

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 31 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 63 REFERENCES

Immunotherapy and tumor microenvironment.

VIEW 2 EXCERPTS

Vaccine adjuvants as potential cancer immunotherapeutics

VIEW 1 EXCERPT

Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.

VIEW 2 EXCERPTS